La Jolla Pharmaceutical Company
LJPC
LJPC was delisted on the 19th of August, 2022.
0 hedge funds and large institutions have $0 invested in La Jolla Pharmaceutical Company in 2022 Q3 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 41 closing their positions.
66.06% less ownership
Funds ownership: 66.06% → 0% (-66%)
100% less funds holding
Funds holding: 41 → 0 (-41)
100% less funds holding in top 10
Funds holding in top 10: 3 → 0 (-3)
100% less capital inflows, than outflows
Capital inflows: $0 | Capital outflows: $53.9M
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 41
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCM
Tang Capital Management
San Diego,
California
|
-$30.6M |
| 2 |
RTW Investments
New York
|
-$7.42M |
| 3 |
HP
HealthInvest Partners
Stockholm,
Sweden
|
-$4.04M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
-$2.63M |
| 5 |
D.E. Shaw & Co
New York
|
-$1.86M |
LJPC Hedge Fund Activity: Q3 2022 in Review
0 of the 5,832 institutional investors tracked by Wall St. Rank reported a position in La Jolla Pharmaceutical Company (LJPC) for Q3 2022, worth a combined $0 — down 100% from $53.9M a quarter earlier.
Sellers outnumbered buyers: 41 funds closed out of LJPC and 0 opened new positions — a net loss of 41 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was Tang Capital Management, exiting entirely with an estimated $30.6M sold.
- 0 institutional investors held La Jolla Pharmaceutical Company (LJPC) as of Q3 2022, down from 41 in Q2 2022.
- Funds reported $0 of La Jolla Pharmaceutical Company stock for Q3 2022, down 100% quarter-over-quarter.
- 0 funds opened new La Jolla Pharmaceutical Company positions in Q3 2022 and 41 closed out, a net change of -41 holders.
- The largest La Jolla Pharmaceutical Company seller in Q3 2022 was Tang Capital Management, an estimated $30.6M sold.
Based on aggregated 13F filings for Q3 2022.